



Malcolm Campbell Memorial Prize 2017 Announcement of Winners **Osimertinib Team**

The Royal Society of Chemistry Biological and Medicinal Chemistry Sector is proud to announce the winners of the Malcolm Campbell Memorial Prize for 2017.

The prize has been awarded to **Sam Butterworth, Darren Cross, Ray Finlay, Richard A Ward and Michael J Waring** for contributions to the team that discovered TAGRISSO^(TM) (osimertinib, AZD9291) at AstraZeneca.

Osimertinib, a potent, oral, CNS-active, irreversible epidermal growth factor receptor (EGFR) inhibitor that was developed specifically for the treatment of patients with T790M mutation positive NSCLC, has demonstrated significant clinically meaningful improvement in efficacy compared to standard of care chemotherapy in these patients, with fewer serious adverse events. In record time, just 2 years and 9 months after the first patient was dosed, osimertinib was provisionally approved for patients whose tumours have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has progressed due to resistance to other EGFR-blocking therapy.

The BMCS Committee wishes to express its gratitude for the high-quality entries from both academia and industry for the 2017 award.

The Malcolm Campbell Memorial prize commemorates Professor Campbell's outstanding contributions in a broad range of chemistry and their applications to the understanding of bioactivity. The prize will be presented formally to the winning team during the 19th RSC / SCI Medicinal Chemistry Symposium to be held at Churchill College in Cambridge on 10th - 13th September 2017.